Begg A C, Hofland I, Kummermehr J
Department of Experimental Radiotherapy, Netherlands Cancer Institute, Amsterdam.
Eur J Cancer. 1991;27(5):537-43. doi: 10.1016/0277-5379(91)90211-u.
This study tested whether the potential doubling time of tumour cells measured before or during treatment could predict the repopulation rate of surviving clonogens during fractionated radiotherapy. Tumours used for the study were a fibrosarcoma (SSK 2), an adenocarcinoma (AT 7) and a squamous cell carcinoma (AT 478), all grown subcutaneously in the C3H mouse. Potential doubling times (Tpot) were measured using the thymidine nanalogue iododexyuridine (IUdR) and flow cytometry. Results were compared with previous radiobiological studies on these tumours in which repopulation rates during radiotherapy were estimated using the tumour growth delay and tumour cure assays. Fractionated treatments consisted of daily doses of 4 or 8 Gy to clamped (hypoxic) tumours, 6 days per week for 1-3 weeks. Tpot values increased markedly during therapy for two of the tumours (SSK 2 and AT 478), by a factor of more than 10 for AT 478 in the third treatment week. Tpot remained approximately constant for the third tumour (AT 7). In no case was there evidence from the labelling studies of a shortening of Tpot which would suggest accelerated repopulation. From the radiobiological data, effective clonogen doubling times during radiotherapy were calculated from the doses required to produce a given effect in short and long treatment schedules. In the second week of treatment, effective clonogen doubling times in two tumours were approximately equal to the pretreatment Tpot, and shorter than the pretreatment Tpot in the third tumour. At some time during treatment, the surviving clonogens in these tumours therefore proliferated at the same rate or faster than before treatment. The difference between the labelling and radiobiological measurements was ascribed to the fact that, shortly after the start of a fractionated treatment, the IUdR labelling technique measures primarily doomed cells. These results show that kinetic measurements using DNA labelling techniques made during fractionated radiotherapy in most cases do not reflect the proliferation status of the surviving cells which are responsible for treatment outcome. Pretreatment Tpot measurements give a much better indication of the proliferation rate of surviving cells but in some cases may underestimate repopulation during radiotherapy.
本研究检测了在治疗前或治疗期间测量的肿瘤细胞潜在倍增时间是否能够预测分次放疗期间存活克隆原的再增殖率。用于该研究的肿瘤包括纤维肉瘤(SSK 2)、腺癌(AT 7)和鳞状细胞癌(AT 478),均在C3H小鼠皮下生长。使用胸腺嘧啶核苷类似物碘脱氧尿苷(IUdR)和流式细胞术测量潜在倍增时间(Tpot)。将结果与先前对这些肿瘤的放射生物学研究进行比较,在先前的研究中,使用肿瘤生长延迟和肿瘤治愈试验估计放疗期间的再增殖率。分次治疗包括每周6天、持续1 - 3周,每天对钳夹(缺氧)肿瘤给予4或8 Gy的剂量。对于其中两种肿瘤(SSK 2和AT 478),Tpot值在治疗期间显著增加,在第三个治疗周,AT 478增加了10倍以上。对于第三种肿瘤(AT 7),Tpot大致保持恒定。在任何情况下,标记研究均未显示Tpot缩短的证据,而Tpot缩短表明再增殖加速。根据放射生物学数据,从在短疗程和长疗程中产生给定效应所需的剂量计算放疗期间有效的克隆原倍增时间。在治疗的第二周,两种肿瘤中有效的克隆原倍增时间大约等于治疗前的Tpot,而在第三种肿瘤中则短于治疗前的Tpot。因此,在治疗的某个时间点,这些肿瘤中存活的克隆原以与治疗前相同或更快的速度增殖。标记测量与放射生物学测量之间的差异归因于这样一个事实,即在分次治疗开始后不久,IUdR标记技术主要测量注定要死亡的细胞。这些结果表明,在分次放疗期间使用DNA标记技术进行的动力学测量在大多数情况下并不能反映负责治疗结果的存活细胞的增殖状态。治疗前的Tpot测量能更好地指示存活细胞的增殖率,但在某些情况下可能会低估放疗期间的再增殖情况。